cancer sequencing
With a new $16 million NCI grant, Count Me In is working with the Broad and Dana-Farber to engage osteosarcoma and leiomyosarcoma patients in their own care and in research.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
Congenica, Gabriel Precision Oncology Partner on Clinical Interpretation for Somatic Cancer Testing
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Increased incidental detection of clonal hematopoiesis and new considerations for mutations in myelodysplastic precursors herald improved precision medicine strategies.